Radiomics for the Prediction of Response to Antifibrotic Treatment in Patients with Idiopathic Pulmonary Fibrosis: A Pilot Study.
Cheng-Chun YangChin-Yu ChenYu-Ting KuoChing-Chung KoWen-Jui WuChia-Hao LiangChun-Ho YunWei-Ming HuangPublished in: Diagnostics (Basel, Switzerland) (2022)
Antifibrotic therapy has changed the treatment paradigm for idiopathic pulmonary fibrosis (IPF); however, a subset of patients still experienced rapid disease progression despite treatment. This study aimed to determine whether CT-based radiomic features can predict therapeutic response to antifibrotic agents. In this retrospective study, 35 patients with IPF on antifibrotic treatment enrolled from two centers were divided into training ( n = 26) and external validation ( n = 9) sets. Clinical and pulmonary function data were collected. The patients were categorized into stable disease (SD) and progressive disease (PD) groups based on functional or radiologic criteria. From pretreatment non-enhanced high-resolution CT (HRCT) images, twenty-six radiomic features were extracted through whole-lung texture analysis, and six parenchymal patterns were quantified using dedicated imaging platforms. The predictive factors for PD were determined via univariate and multivariate logistic regression analyses. In the training set (SD/PD: 12/14), univariate analysis identified eight radiomic features and ground-glass opacity percentage (GGO%) as potential predicators of PD. However, multivariate analysis found that the single independent predictor was the sum entropy (accuracy, 80.77%; AUC, 0.75). The combined sum entropy-GGO% model improved the predictive performance in the training set (accuracy, 88.46%; AUC, 0.77). The overall accuracy of the combined model in the validation set (SD/PD: 7/2) was 66.67%. Our preliminary results demonstrated that radiomic features based on pretreatment HRCT could predict the response of patients with IPF to antifibrotic treatment.
Keyphrases
- idiopathic pulmonary fibrosis
- high resolution
- end stage renal disease
- computed tomography
- chronic kidney disease
- newly diagnosed
- ejection fraction
- squamous cell carcinoma
- stem cells
- magnetic resonance
- risk assessment
- magnetic resonance imaging
- machine learning
- contrast enhanced
- prognostic factors
- mass spectrometry
- combination therapy
- positron emission tomography
- electronic health record
- artificial intelligence
- liquid chromatography
- image quality
- pet ct
- human health
- tandem mass spectrometry